ISLET Act

This bill clarifies that human cadaveric islet transplants (cells from deceased donors used in diabetes treatment) are not classified as "drugs," "biological products," or "HCT/Ps" under existing federal law. It amends the Public Health Service Act to explicitly include "human cadaveric islets" in regulatory references, ensuring these transplants are not subject to the same oversight as pharmaceuticals or other biological products. The bill requires the Health Secretary to update relevant regulations within one year of enactment and report progress to Congress within six months. This change directly affects how the FDA and other agencies regulate islet transplants, streamlining their approval process without altering medical practice.